JP2017518040A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518040A5 JP2017518040A5 JP2016563850A JP2016563850A JP2017518040A5 JP 2017518040 A5 JP2017518040 A5 JP 2017518040A5 JP 2016563850 A JP2016563850 A JP 2016563850A JP 2016563850 A JP2016563850 A JP 2016563850A JP 2017518040 A5 JP2017518040 A5 JP 2017518040A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- region shown
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 18
- 239000000611 antibody drug conjugate Substances 0.000 claims 17
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 17
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims 11
- 229940127089 cytotoxic agent Drugs 0.000 claims 11
- 239000002254 cytotoxic agent Substances 0.000 claims 11
- 231100000599 cytotoxic agent Toxicity 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 102000052942 human RNF43 Human genes 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical group C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 210000005102 tumor initiating cell Anatomy 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 101000802406 Homo sapiens E3 ubiquitin-protein ligase ZNRF3 Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 102000047156 human ZNRF3 Human genes 0.000 claims 1
- 238000004237 preparative chromatography Methods 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461982294P | 2014-04-21 | 2014-04-21 | |
| US61/982,294 | 2014-04-21 | ||
| PCT/US2015/026904 WO2015164392A2 (en) | 2014-04-21 | 2015-04-21 | Novel antii-rnf43 antibodies and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017518040A JP2017518040A (ja) | 2017-07-06 |
| JP2017518040A5 true JP2017518040A5 (OSRAM) | 2018-06-21 |
Family
ID=54333409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563850A Pending JP2017518040A (ja) | 2014-04-21 | 2015-04-21 | 新規の抗ｒｎｆ４３抗体および使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20170073430A1 (OSRAM) |
| EP (1) | EP3134121A4 (OSRAM) |
| JP (1) | JP2017518040A (OSRAM) |
| KR (1) | KR20170010764A (OSRAM) |
| CN (1) | CN106714831A (OSRAM) |
| AU (1) | AU2015249887A1 (OSRAM) |
| BR (1) | BR112016024525A2 (OSRAM) |
| CA (1) | CA2946308A1 (OSRAM) |
| CL (2) | CL2016002667A1 (OSRAM) |
| CR (1) | CR20160486A (OSRAM) |
| DO (1) | DOP2016000283A (OSRAM) |
| EA (1) | EA201692100A8 (OSRAM) |
| IL (1) | IL248399A0 (OSRAM) |
| MA (1) | MA39896A (OSRAM) |
| MX (1) | MX2016013857A (OSRAM) |
| PH (1) | PH12016502061A1 (OSRAM) |
| SG (1) | SG11201608715WA (OSRAM) |
| WO (1) | WO2015164392A2 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2647707T (lt) | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
| TW201800420A (zh) * | 2016-05-20 | 2018-01-01 | 艾伯維史坦森特瑞斯有限責任公司 | 抗ascl1抗體及使用方法 |
| US11993645B2 (en) * | 2017-01-11 | 2024-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising R-Spondin (RSPO) surrogate molecules |
| WO2018140821A1 (en) | 2017-01-26 | 2018-08-02 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
| JP2020518584A (ja) * | 2017-05-02 | 2020-06-25 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
| US12215154B2 (en) | 2018-01-19 | 2025-02-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting γδ T cells with chimeric antigen receptors |
| AU2019301633A1 (en) * | 2018-07-09 | 2021-01-28 | Surrozen Operating, Inc. | Tissue-specific Wnt signal enhancing molecules and uses |
| CA3118692A1 (en) * | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| EP3986912A1 (en) | 2019-06-21 | 2022-04-27 | Regeneron Pharmaceuticals, Inc. | Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors |
| JP2023549854A (ja) | 2020-11-16 | 2023-11-29 | スロゼン オペレーティング， インコーポレイテッド | 肝臓特異的Ｗｎｔシグナル増強分子およびその使用 |
| US20240002479A1 (en) * | 2020-11-23 | 2024-01-04 | The Regents Of The University Of Michigan | Single-chain antibody against flavivirus ns1 protein |
| CN112480250B (zh) * | 2020-12-23 | 2022-03-15 | 上海交通大学 | 一种抗人骨桥蛋白的抗体及其应用 |
| WO2022169872A1 (en) * | 2021-02-03 | 2022-08-11 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
| CA3211478A1 (en) | 2021-03-16 | 2022-09-22 | Naoya Tsurushita | Bifunctional molecules for treatment of immune disorders |
| CN113372447A (zh) * | 2021-05-26 | 2021-09-10 | 重庆中元汇吉生物技术有限公司 | 抗pivka-ii单克隆抗体及其应用 |
| CA3262929A1 (en) * | 2022-07-25 | 2024-02-01 | Sloan Kettering Inst Cancer Res | PREPARATION PROCESSES FOR ADOPTIVE CELL THERAPIES |
| CN116120444A (zh) * | 2023-02-28 | 2023-05-16 | 中国人民解放军军事科学院防化研究院 | 一种用于检测SARS-CoV-2病毒N蛋白的纳米抗体及检测卡制备 |
| CN117801108B (zh) * | 2023-12-06 | 2024-06-07 | 无锡傲锐东源生物科技有限公司 | 抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用 |
| CN118652345B (zh) * | 2024-06-28 | 2025-04-15 | 杭州华葵金配生物科技有限公司 | 幽门螺旋杆菌b型尿素酶抗体及其应用 |
| CN119462949B (zh) * | 2025-01-09 | 2025-04-01 | 中国农业科学院农业质量标准与检测技术研究所 | 一种抗β-内酰胺酶的抗体或其抗原结合片段、生物产品及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101613405A (zh) * | 2002-06-06 | 2009-12-30 | 肿瘤疗法科学股份有限公司 | 与人结肠癌相关的基因和多肽 |
| HRP20140172T1 (hr) * | 2006-05-30 | 2014-03-28 | Genentech, Inc. | Protutijela i imunokonjugati kao i njihove uporabe |
| JP2014530816A (ja) * | 2011-10-14 | 2014-11-20 | ノバルティスアーゲー | Ｗｎｔ経路関連疾患のための抗体および方法 |
| RU2017120287A (ru) * | 2012-02-28 | 2018-11-15 | АйАрЭм ЭлЭлСи | ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43 |
-
2015
- 2015-04-21 JP JP2016563850A patent/JP2017518040A/ja active Pending
- 2015-04-21 EA EA201692100A patent/EA201692100A8/ru unknown
- 2015-04-21 MA MA039896A patent/MA39896A/fr unknown
- 2015-04-21 CA CA2946308A patent/CA2946308A1/en not_active Abandoned
- 2015-04-21 KR KR1020167032459A patent/KR20170010764A/ko not_active Withdrawn
- 2015-04-21 AU AU2015249887A patent/AU2015249887A1/en not_active Abandoned
- 2015-04-21 MX MX2016013857A patent/MX2016013857A/es unknown
- 2015-04-21 EP EP15783044.9A patent/EP3134121A4/en not_active Withdrawn
- 2015-04-21 BR BR112016024525A patent/BR112016024525A2/pt not_active IP Right Cessation
- 2015-04-21 SG SG11201608715WA patent/SG11201608715WA/en unknown
- 2015-04-21 WO PCT/US2015/026904 patent/WO2015164392A2/en not_active Ceased
- 2015-04-21 CR CR20160486A patent/CR20160486A/es unknown
- 2015-04-21 CN CN201580033599.1A patent/CN106714831A/zh active Pending
- 2015-04-21 US US15/305,861 patent/US20170073430A1/en not_active Abandoned
-
2016
- 2016-10-17 PH PH12016502061A patent/PH12016502061A1/en unknown
- 2016-10-19 IL IL248399A patent/IL248399A0/en unknown
- 2016-10-19 DO DO2016000283A patent/DOP2016000283A/es unknown
- 2016-10-20 CL CL2016002667A patent/CL2016002667A1/es unknown
-
2017
- 2017-12-15 CL CL2017003240A patent/CL2017003240A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518040A5 (OSRAM) | ||
| US12331117B2 (en) | Antibody molecules which bind CD22 | |
| US11261252B2 (en) | Molecules with specificity for CD79 and CD22 | |
| JP2016531914A5 (OSRAM) | ||
| JP2016531915A5 (OSRAM) | ||
| JP6998857B2 (ja) | Ｃｄ７９に結合する抗体分子 | |
| JP2017500028A5 (OSRAM) | ||
| JP2015509948A5 (OSRAM) | ||
| JP2016536020A5 (OSRAM) | ||
| PE20200862A1 (es) | Anticuerpos anti-trem2 y metodos relacionados | |
| IL317587A (en) | Antibody against SIRPalpha | |
| JP2017535246A5 (OSRAM) | ||
| JP2017529838A5 (OSRAM) | ||
| PE20220575A1 (es) | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3 | |
| JP2011046732A5 (OSRAM) | ||
| JP2013519364A5 (OSRAM) | ||
| JP2016538318A5 (OSRAM) | ||
| HRP20140502T1 (hr) | Humanizirana anti-cxcr4 antitijela za lijeäśenje karcinoma | |
| PE20210554A1 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
| PE20191075A1 (es) | Anticuerpo que se une especificamente a il-17a y fragmento funcional del mismo | |
| JP2010509931A5 (OSRAM) | ||
| JP2021512652A5 (OSRAM) | ||
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| JP7016367B2 (ja) | 多特異性抗体の凝集を低減するための抗体フレームワーク | |
| IL277899B2 (en) | Methods and preparations for treating yellow fever |